1. Medtech Insight
  2. >>Business
  3. >>Deals

M&A Analysis: No Spring For March Mergers

 
• By Catherine Longworth

M&A deal activity waned in March, with a total of 9 deals completed in the month, down from 12 in February and 17 in March 2016. This third month brought the total number of deals for Q1 2017 to 33, a significant year-on-year decline compared to 51 in the first quarter of 2016.

Merging Business Network-Business leaders in global agreement
M&A activity declined in March to 9 deals, compared to 12 in January and February • Source: Shutterstock

The seasons might be changing but the downward trend in M&A activity continued into March, with Medtech Insight's M&A deal tracker recording nine deals only for the month. The March total was down from 12 deals recorded in February and significantly down from the 17 recorded a year ago in March 2016. None of the deals last month disclosed their financial terms.

Figure 1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

PathAI Expands AISight Dx Label With PCCP-Guided Addition Of Roche Scanners

 
• By Natasha Barrow

Roche’s scanners have been integrated with PathAI’s AISight Dx system. The system’s FDA-cleared PCCP allows new components to be validated and integrated without additional FDA clearance. Eric Walk, chief medical officer, hints at future biopharma companion diagnostic collaborations.

Salient Bio Raises £2.35M For March 2026 Rollout Of At-Home IBD Microbiome Test

 
• By Natasha Barrow

Salient's inflammatory bowel disease test, built on the start-up’s Signal platform, is planned to launch in March 2026. The company leverages rich data from existing wellness tests to develop signatures, focusing on conditions that are often misdiagnosed and disproportionately affect women.

Tempus AI Buys Paige For $81.25M To Help Build Largest Oncology Foundation Model

 
• By Marion Webb

Tempus expects its $81.25m acquisition of Paige AI to accelerate building the largest oncology foundation model. With its third deal this year, Tempus expands capabilities across genomics, pathology, and clinical trials.

Terumo’s $1.5Bn Buyout Of OrganOx Vaults Company Into Organ Preservation Market

 
• By Marion Webb

Terumo will acquire OrganOx for about $1.5bn, adding the only FDA-cleared liver normothermic perfusion device to its portfolio. Analysts don’t expect the buyout to have a significant impact on competition, but the deal marks a strategic shift for Terumo into transplant medicine.

More from Business

Highridge Medical CEO Whitney On Accelus Buys And Spine Strategy

 
• By Ashley Yeo

After divesting bone healing products in mid-year, Highridge Medical doubled down on its spine capabilities with a triple purchase of technologies from Accelus, bringing access to “Adaptive Geometry.” CEO Rebecca Whitney explained Highridge’s strategy.

Salient Bio Raises £2.35M For March 2026 Rollout Of At-Home IBD Microbiome Test

 
• By Natasha Barrow

Salient's inflammatory bowel disease test, built on the start-up’s Signal platform, is planned to launch in March 2026. The company leverages rich data from existing wellness tests to develop signatures, focusing on conditions that are often misdiagnosed and disproportionately affect women.

Abbott’s Navitor TAVR Wins CE Mark Expansion, New Guidelines Allow Treatment For Younger Patients

 
• By Marion Webb

Abbott’s Navitor TAVR system is now CE-marked for low to intermediate risk patients, based on positive data from the Vintage trial. The EACTS guidelines for TAVR lowered the recommended age for patients with severe aortic stenosis to 70 years and older, which opens up treatment for younger patients.